Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A
Format:	Journal article
Sprache:	English
Veröffentlicht:	Springer Nature 2020

Ähnliche Einträge

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
von: Fidler, C, et al.
Veröffentlicht: (2004)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
von: Ramy Rahmé, et al.
Veröffentlicht: (2023-04-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
von: Čolović Nataša, et al.
Veröffentlicht: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
von: Lijuan Zhang, et al.
Veröffentlicht: (2023-12-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
von: Haase, D, et al.
Veröffentlicht: (2019)

SF3B1 mutant myelodysplastic syndrome: Recent advances
von: Pellagatti, A, et al.
Veröffentlicht: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
von: Pimjai Niparuck, et al.
Veröffentlicht: (2021-10-01)

Gene expression profiling in the myelodysplastic syndromes.
von: Pellagatti, A, et al.
Veröffentlicht: (2005)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
von: Pellagatti, A, et al.
Veröffentlicht: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
von: Davidson Zhao, et al.
Veröffentlicht: (2023-03-01)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (2014)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
von: Daver, NG, et al.
Veröffentlicht: (2022)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
von: Laurence Lodé, et al.
Veröffentlicht: (2018-01-01)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
von: Rashmi Kanagal-Shamanna, et al.
Veröffentlicht: (2021-03-01)

A tale of two alleles: TP53 and transformation in MPNs
von: Brierley, C, et al.
Veröffentlicht: (2022)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
von: Liberante, F, et al.
Veröffentlicht: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
von: Liberante, F, et al.
Veröffentlicht: (2013)

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should
von: Corey Cutler
Veröffentlicht: (2017-12-01)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
von: Fernando Barroso Duarte, et al.
Veröffentlicht: (2017-05-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
von: Armstrong, R, et al.
Veröffentlicht: (2017)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
von: Nikeeta Mandhan, et al.
Veröffentlicht: (2022-01-01)

Clonality in the myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (2001)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
von: David A. Sallman
Veröffentlicht: (2020-06-01)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
von: Y. Fang, et al.
Veröffentlicht: (2022-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
von: Shyam A. Patel, et al.
Veröffentlicht: (2023-11-01)

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
von: Yi Chen, et al.
Veröffentlicht: (2023-11-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
von: Kathy L. McGraw, et al.
Veröffentlicht: (2016-08-01)

Molecular pathogenesis of the myelodysplastic syndromes
von: Boultwood, J, et al.
Veröffentlicht: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
von: Boultwood, J, et al.
Veröffentlicht: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
von: Melania Tesio
Veröffentlicht: (2023-02-01)

Telomere length in myelodysplastic syndromes.
von: Boultwood, J, et al.
Veröffentlicht: (1995)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
von: Nabih Maslah, et al.
Veröffentlicht: (2020-06-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
von: Yuxin Wang, et al.
Veröffentlicht: (2022-07-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
von: Pellagatti, A, et al.
Veröffentlicht: (2003)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
von: Haiwei Wang, et al.
Veröffentlicht: (2022-06-01)

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia
von: Doolittle, H
Veröffentlicht: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
von: Alexander Quaas, et al.
Veröffentlicht: (2019-01-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
von: Pellagatti, A, et al.
Veröffentlicht: (2008)

P066: Variant overlooked: A partial deficiency TP53 allele that skirts interpretation criteria
von: Lisa Lansdon, et al.
Veröffentlicht: (2023-01-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
von: Papaemmanuil, E, et al.
Veröffentlicht: (2013)